Evidence map›Paper›PMID 36380764›Full record

ArticlebioRxiv : the preprint server for biology2022

Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles.

Emma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, Noshin Hussain, Pehuén Pereyra Gerber, Hiu-Long Shum, Chloe Rees-Spear, Luke Muir, Ester Gea-Mallorquí, Jakub Kopycinski and 19 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 7 institutions in 1 country.

Emma TouizerInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Aljawharah AlrubbayiInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Rosemarie FordInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Noshin HussainInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Pehuén Pereyra GerberCambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, UK.
Hiu-Long ShumInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Chloe Rees-SpearInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Luke MuirInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Ester Gea-MallorquíNuffield Department of Medicine, University of Oxford, UK.
Jakub KopycinskiNuffield Department of Medicine, University of Oxford, UK.
Dylan JankovicInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Christopher PinderInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Thomas A FoxInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Ian WilliamsMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, UK.
Claire MullenderInstitute for Global Health, University College London, UK.
Irfaan MaanMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, UK.
Laura WatersMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, UK.
Margaret JohnsonInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Sara MadgeThe Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust UK.
Michael YouleInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Tristan BarberInstitute for Global Health, University College London, UK.
Fiona BurnsInstitute for Global Health, University College London, UK.
Sabine KinlochInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Sarah Rowland-JonesNuffield Department of Medicine, University of Oxford, UK.
Richard GilsonMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, UK.
Nicholas J MathesonCambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, UK.
Emma MorrisInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Dimitra PeppaInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Laura E McCoyInstitute for Immunity and Transplantation, Division of Infection and Immunity, University College London, UK.
Centre for Immunity, Infection and Evolution · GBThe Royal Free Hospital · GBMortimer Market Centre · GBUniversity of Oxford · GBNHS Blood and Transplant · GBUniversity College London · GBUniversity of Cambridge · GB

Funding

Medical Research Council MC_PC_20060
6 · The paper itself

Abstract

People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can have residual immune dysfunction and often display poorer responses to vaccination. We assessed in a cohort of PLWH (n=110) and HIV negative controls (n=64) the humoral and spike-specific B-cell responses following 1, 2 or 3 SARS-CoV-2 vaccine doses. PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls at all studied timepoints. Moreover, their neutralization breadth was reduced with fewer individuals developing a neutralizing response against the Omicron variant (BA.1) relative to controls. We also observed a delayed development of neutralization in PLWH that was underpinned by a reduced frequency of spike-specific memory B cells (MBCs) and pronounced B cell dysfunction. Improved neutralization breadth was seen after the third vaccine dose in PLWH but lower nAb responses persisted and were associated with global, but not spike-specific, MBC dysfunction. In contrast to the inferior antibody responses, SARS-CoV-2 vaccination induced robust T cell responses that cross-recognized variants in PLWH. Strikingly, a subset of PLWH with low or absent neutralization had detectable functional T cell responses. These individuals had reduced numbers of circulating T follicular helper cells and an enriched population of CXCR3

Identifiers

PMID36380764
PMCPMC9665338
OpenAlexW4308844443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.